Lung Cancer Screening and Quit Support: What CASTL Tests for Value

If you qualify for annual lung cancer screening with a low-dose CT scan (LDCT), that visit can be more than just a scan. It can also be a practical moment to get quit-smoking help—because smoking is the leading cause of lung cancer, and quitting can meaningfully lower risk.

One of the newest research updates in this space comes from CASTL (Cessation and Screening to Save Lives), an optimization randomized clinical trial designed to figure out which mix of evidence-based quit-support components may be the most “value-efficient” to deliver in lung screening settings.

Why quit support matters right when LDCT screening is happening

LDCT screening is recommended only for people at higher risk based on age and smoking history—not for people who have symptoms. For many people, the screening visit is already a structured health-care touchpoint, which can make it easier to offer cessation support without treating quitting as a separate “extra.”

At the same time, screening involves real tradeoffs. CDC lists harms such as false-positive results (which can lead to follow-up tests), overdiagnosis (finding cancers that might not have caused harm), and radiation exposure from repeated scans—so the screening visit typically includes shared decision-making.

What the newest CASTL trial tested in lung screening settings

CASTL used a multiphase optimization (MOST) approach to test four evidence-based tobacco treatment components, both delivered alone and in combination. According to the trial description from the National Cancer Institute (NCI), the component set included:

Motivational interviewing counseling (with two sessions tied to the screening timeline, including a follow-up session weeks later).
Individualized quitting messages with different message framing (for example, loss-framed vs gain-framed messages).
Nicotine replacement therapy (NRT) in different forms—an OTC patch and/or lozenges.
Enhanced standard of care, including self-help cessation materials and referral to a Quitline.

Participants were randomized to one of multiple component “groups,” then followed after the screening period (the trial description notes follow-up at 3 and 6 months).

What the early results do—and do not—show

In the CASTL early published abstract, researchers reported no statistically significant abstinence differences among the tested component combinations (as summarized in the abstract). That means the abstract-level reporting does not point to one clear “winner” on quitting outcomes.

However, the abstract also includes an efficiency-oriented analysis that estimates which approach may be most “value-efficient” based on expected abstinence and mean cost in the trial’s framework. In other words, it’s a way to help prioritize what a program emphasizes when resources are limited.

What “most value-efficient” means in plain language

In this context, “most value-efficient” is not a guarantee that everyone given that approach will quit. It’s a planning estimate that combines two ideas:

Expected abstinence (how quitting might be expected to differ across component mixes), and
Cost (how much the components are expected to cost to deliver).

Based on the abstract, the most value-efficient option described was a combination using loss-framed messaging plus nicotine patch and lozenges. The key takeaway for readers is: during an LDCT screening workflow, it may be possible to prioritize a quit-support package that aims for the best balance of expected quitting and program cost—while still recognizing that final, full outcomes are not established from abstract-level reporting alone.

Who is eligible for annual LDCT screening (U.S. guidance)

CDC summarizes U.S. screening eligibility as adults who:

Are between 50 and 80 years old
Have a 20 pack-year or more smoking history
Smoke now or quit within the past 15 years

Screening is for people without lung cancer symptoms; if you have concerning symptoms, that’s a different medical situation than routine screening.

Medicare coverage basics for lung cancer screening

Medicare Part B covers lung cancer screening with LDCT once a year if you meet these key conditions (among others) listed on Medicare.gov:

You’re between 50 and 77
You don’t have signs or symptoms of lung cancer (you’re asymptomatic)
You’re a current smoker or you quit within the last 15 years
You have a tobacco history of at least 20 pack years
You get an order from your health care provider

Medicare.gov also notes that you need a provider appointment before your first screening to discuss benefits and risks, and that you pay nothing if your provider accepts assignment. Out-of-pocket costs can still vary for additional or follow-up services.

What to ask for at your LDCT screening visit (a CASTL-aligned checklist)

If you’re currently smoking (or recently quit) and you’re going through LDCT screening, consider asking whether your screening team can offer quit support in the following component categories:

Counseling: Do you offer motivational-interviewing style cessation counseling as part of the screening workflow?
Personalized messages: Can you provide individualized quitting information (including different message-framing approaches) tailored to my situation?
NRT options: Are nicotine replacement options available (for example, patch and/or lozenges)? If so, what’s appropriate and safe for me?
Follow-up: What happens after the scan—how soon will you connect me to counseling or cessation support?
Quitline/referrals: Can you connect me to Quitline resources or a structured cessation program?

Safety note: NRT isn’t automatically right for everyone. Ask your clinician what’s safe for your medical history and current medications.

Bottom line: what’s ready now vs. what’s still uncertain

Ready to use now: Treat the LDCT screening visit as an opportunity to ask for structured quit support—especially counseling, NRT options, and a follow-up plan.
Still uncertain: The CASTL abstract-level findings reported no statistically significant abstinence differences among component mixes, so readers shouldn’t assume one exact combination will be best for everyone. Full, detailed results (published beyond the abstract) matter before standardizing a single approach.

Sources

Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.

This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.